This report reviews developments in the early diagnosis and staging of prostate cancer and updated on the incidence of postate cancer to discuss the pros and cons of population based screening. Re®nements and reliability of various diagnosic procedures are described such as PSA testing, transrectal ultrasound, ratio beteen PSA-level and ultrasound measured prostate volume, rate of change of PSA-level, combination factor equations computed by neural network programs to predict likelihood of prostate cancer, arti®cial neural network analysis of subvisual transrectal ultrasound information, measurements of different PSAforms of PSA (in particular percent free PSA), and glandular kallikrein 2.
In the 4th Scienti®c Session on Early Diagnosing and Staging, Dr J Moul, Associate Professor of Surgery at the Uniformed Services University of the Health Sciences, Bethesda, Maryland, discussed both`Maximizing PSA for Prostate Cancer Detection' and`Stage/Grade Migration'. The ten years of the`PSA-era' has dramatically altered the incidence rates of and clinical stage at which most cases of prostate cancer cases are diagnosed in the United States and many other industrialized countries. Since 1990, the reported number of new cases diagnosed with prostate cancer has increased sharply in the United States. According to scientist at the National Cancer Institute (NCI), 1 the age-adjusted incidence rates increased in the United States by 3% from 1981±1984, it increased by 20% from 1985±1988, whereas the incidence rate increased by about 70% from 1989±1992. For white men, the incidence rate peaked in 1992, and dropped by almost 30% in 1994, and it is believed that the increased use of PSA-testing in serum resulted in an arti®cial rise in the incidence rates after 1989. In 1988, the PSA-test was requested at a rate of about 1400 tests per 100 000 men compared to 18 000 tests per 100 000 men in 1991. Prostate cancer is now the most common malignancy in American men and in many countries in Europe, and the American Cancer Society estimated that 210 000 men would be diagnosed during 1997 in the United States. 2 The tumor is the second most common cause of death in men with malignant diseases in the USA, and the most common cause of death in men with malignant disease in Sweden. By the SEER (Surveillance, Epidemiology, and Results) data from the US National Cancer Institute, mortality rates have been gradually rising but now declined by 6.3% from 1991±1995, though the cause of this decline are presently unknown. 3 The researchers at NCI presently consider it unlikely that the recent decrease in deaths from prostate cancer may be due to the increase in PSAdetected cancer. Instead, it may take 5 y of`lead-time' before there would be a drop in mortality possibly prevented by treating early stage disease as the PSA-screening is estimated to detect the cancer 5 y or more before any symptoms appear.
In the past ten years, the SEER data also show a stagemigration with a declining rate of distant (metastatic) disease. 1 At initial presentation, it is now rare in the United States that men have advanced stage D 2 with impending spinal cord compression or urinary retention and the SEER age-adjusted incidence rate of distant disease has decreased from about 14/100 000 to close to half, about 7/100 000 in the years from 1990±1994.
1 Dr Moul stated that this trend is also re¯ected in the database of the Department of Defense Center for Prostate Disease at Walter Reed Medical Center where the percentage of stage D disease ranged from 13±20% in 1988±1990 which decreased to 5% in 1995±1996. By contrast, the rate of PSA-detected cancer, stage T 1c , increased from 0% in 1988 to 46 in 1996, whereas the clinically localized palpable disease, stage T 2 , decreased from 50% in the late 1980 to about 30% of the cases in the last few years. Despite this trend in stage migration, the SEER data do not suggest that there is a marked increase in predominantly low grade (Gleason scores 2±4) potentially unimportant tumors diagnosed as a result of wide-spread use of PSA-testing to detect the cancers.
1 By contrast, there is an increase in the rate of detection of moderate grade (Gleason scores 5±7) prostate cancer according to the database at Walter Reed Army Medical Center.
On the basis of these incidence ®gures, Dr Moul then went on to discuss the pros and cons of population-based PSA Screening. To be of value, screening has to result in a favorable impact on prognosis and Catalona et al 4 have reported that screening reduces the incidence of advanced disease with no greater percentage of latent disease. This may be important as, presently, there are no ef®cient therapeutic regimens available for the treatment of prostate cancer at advanced stages whereas the introduction of radical treatment procedures contributes a major change in therapeutic strategy when prostate cancer is diagnosed at early local stage, particularly in the USA. Opponents of screening argues on the potential for side effects from treatment, unnecessary treatments, costs for the health care system, and lack of scienti®c evidence for reduction in disease-speci®c mortality.
Another issue is the reliability of the PSA test as a method of screening for prostate cancer. The sensitivity of the test is sub-optimal as more than 20% of the cancers will stay undetected at the commonly used cut-off level of 4 ng/mL. Furthermore, the speci®city is quite poor as not more than 1/3 of the men with PSA-levels from 4.1± 10.0 ng/mL will be diagnosed with the cancer. 5 Therefore, multiple re®nements have been tested to improve the clinical utility of the PSA-testing. The measurement of the ratio between the PSA-level and the transrectal ultrasound (TRUS) measured prostate volume (PSA-density) employs the assumption that cancerous cells leak more PSA into the blood than benign hyperplastic cells. 6 Another approach is to assess the rate of change of the PSA-level (PSA-velocity), 7 the Prostasure 1 index which uses a neural network computer program to predict likelihood of prostate cancer based on combination factor equations, 8 or age-speci®c reference ranges (ASSRs). 9 However, black men newly diagnosed with prostate cancer have higher serum PSA levels than white men, even after correction for stage, grade, and tumor volume. 10 Furthermore, ASSRs found for the black population were signi®cantly higher compared to those found for white men 11 and when these ASSRs were tested in a group of 411 black men with prostate cancer, the 95th pecentile-based ASSR cutoffs failed to detect 41% of the prostate cancer cases. 11 Therefore, Dr Moul and associates, have developed age-speci®c cut-off levels based on 95% sensitivity in the cancer detection. Instead of computing the reference ranges from the controls, they used the data on the PSA-levels detected in the 411 cases of cancer in black men and 1372 cases in white men to calculate ranges that identify 95% of the cancer cases.
Subsequently, Professor Hans Lilja, at Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital Malmo È , Sweden, discussed`PSA-isoforms and their Value in Diagnosis.' The studies of Christensson et al, 12 Lilja et al, 13 and of Stenman et al 14 were the ®rst to identify the different molecular forms of PSA in the blood. Two mainly liverderived protease inhibitors, alpha-1-antichymotrypsin (ACT) and alpha-2-macroglobulin (AMG) occur at large molar excess to PSA in serum. ACT and AMG contributes the major capacity to inactivate PSA escaping from the prostate by forming stable covalent PSA-ACT and PSA-AMG complexes. 12 The PSA-AMG complexes stay undetected by presently available PSA assays as no PSAepitopes are being exposed by the PSA-AMG complex under non-denaturant assaying conditions. 13 However, sensitive and speci®c immunoassays have been developed for the detection of free PSA, PSA-ACT complexes, in addition to total PSA which mainly comprises free PSA and PSA-ACT. 13, 14 Stenman et al 14 and Christensson et al 15 were the ®rst to measure the ratio of PSA-ACT complexes relative to total PSA and showed independently that this ratio was signi®cantly higher in patients with cancer compared to men with benign prostatic hyperplasia (BPH). Inversely, the independently measured ratio free to total PSA ratio (much later often referred to as the percent free PSA) was signi®cantly lower in patients with cancer compared to those with BPH. 15 Furthermore, the serum samples from men with total PSA levels less than 20 ng/mL were used to show that the free-to-total PSA ratio was sign®cantly lower in the untreated patients diagnosed with cancer compared to men with BPH. 15 However, as of today it is still not understood why there is much lower percent free PSA in serum from patients with prostate cancer compared to those from men with BPH. Partly, this may be due to the lack of data on the molecular nature of the free PSA form in blood and why it stays mainly unreactive with the large excess of inhibitors in the blood.
We have developed a dual-label time-resolved immunouorometric assay for simultaneous measurements of the free and total PSA in serum which detects free PSA by less than 0.2% crossreactivity with the PSA-ACT complex, and provides equimolar detection of total PSA. 16 Receiver operation characteristics (ROC) were used to calculate areas under the curve (AUC) for free and total PSA measurements compared in 47 patients with benign hyperplastic glands and 39 with localized prostate cancer, which all had total PSA levels in the 1.0± 20.0 ng/mL range. 16, 17 The AUC was signi®cantly larger for the free-to-total PSA measurements compared to those of total PSA alone. The analysis was extended further to compare the performance of the assays for free PSA, PSA-ACT complex, and total PSA by ROC curve analysis. 17 This showed that the ratio of free-to-total PSA, or that of free PSA-to-PSA-ACT complex gave the largest AUC compared to measuring the free PSA, PSA-ACT-complex, total PSA, or the PSA-ACT-complex-to-total PSA ratio. 17 Recent studies on the utility of different PSA forms in blood have mainly focused on possibilities to improve the analytical speci®city of total PSA-testing with limited loss of analytical sensitivity in early detection of CAP. These issues are now addressed in population based studies on the detection of clinically localized CAP. We are involved in a study where 10 000 randomly selected men at 50±66 y of age in the City of Gothenburg, Sweden were invited for blood sampling to measure free and total PSA levels in serum. 18 In all, 5845 men (about 60% of those invited) volunteered for blood sampling and PSA testing. About 11% of those tested (660 men) had total PSA levels in serum of 3.0 ng/mL or more. More than 90% of these men (610 men) underwent digital rectal examination (DRE), TRUS, and TRUS-guided sextant biopsy. In total, 137 men were diagnosed with prostate cancer (2.3% of the study population) giving a positive predictive value (PPV) of 22% for the total PSA-testing in serum. However, there would have been only 105 men diagnosed with prostate cancer which corresponds to a missed diagnosis in 32 of the cancers (23% loss in sensitivity) with the standard reference range of 4 ng/mL for total PSA in serum. 18 By contrast, there would have been 120 men diagnosed with CAP (corresponding to 11% loss in sensitivity) using the 3.0 ng/mL cut-off for total PSA in conjunction with a cutoff at less than 18% free PSA. Furthermore, this approach reduced the false positives (men with benign histology at biopsy) by about 50%. Thereby, the positive predictive value (PPV) for the total PSA testing of 22.5% increased to a PPV of 33.5% for the combination of free to total PSA measurements. The outcome of this study therefore shows that the high number of false positive test results obtained by total PSA testing in serum alone can be signi®cantly reduced by additional analysis of the percent free PSA at the expense of only limited loss in sensitivity.
Finally, the utility of measurements hK2, recently shown to function in vitro as the converting enzyme which can activate the inactive proPSA into active PSA at physiologically appropriate ratios, 19 have been studied by an indirect scavenger assay procedure. 20 A recently updated version of the assay procedure provides a functional sensitivity of less than 0.05 ng/mL and a crossreactivity to the extensively similar PSA molecule of less than 0.1%. The hK2 immunoreractivity was undetectable in serum from healthy men and women, whereas low concentrations of hK2 were detected in about half of the number of serum samples collected from patients BPH. Most samples from men with localized cancer contained detectable levels of hK2 whereas hK2 was detected in serum from 55/57 men with advanced cancer. This resulted in a median proportion of hK2 to total PSA of about 1.2±1.6% in the different patient groups. Measurements of hK2 discriminated patients with cancer from those without as the hK2 levels in serum were signi®-cantly different in these patient groups. We presently evaluate whether speci®c hK2 measurements add signi®-cant information to that provided by the combination of the free and total PSA measurements and therefore take no de®nitive stand-point on the utility of speci®c hK2 measurements in serum.
Dr T Loch, Department of Urology at the ChristianAlbrechts-Universita È t, Kiel, Germany, went on to discuss Re®nement in Ultrasound Diagnosis.' Hypoechoic areas are the classic problem of visual interpretation of TRUS as they can be either normal or cancerous histologically; about 75% of cancers are hypoechoic but the speci®city of hypoechoic areas are low, and about 25% of the cancers are isoechoic and therefore not distinguishable from the normal areas. 21, 22 Therefore, a new method of Arti®cial Neural Network Analysis (ANNA) has been employed to obtain existing subvisual information from TRUS 23±25 The prospective study evaluated 61 patients with clinically localized prostate cancer diagnosed by biopsy. Each patient was examined by TRUS 1 to 2 days prior to radical retropubic prostatectomy with digital storing of an average of ®ve transverse images labeled from apex of the prostate at 4 mm increments and compared with computer scans of the paraf®n-®xed and stained surgical specimens cut at 4 mm intervals. Tissue sections were evaluated histopathologically and anatomically and matched with the TRUS images. In total, 71% of the malignant samples were hypoechoic, 29% isoechoic, and none was hyperechoic, whereas 78% of the Gleason grade 4/5 samples were hypoechoic and 22% isoechoic. ANNA classi®ed 99% of the samples correctly as benign whereas 79 % were correctly classi®ed as cancers, of which 90 % of the Gleason grade 1±3 samples were correctly classi®ed as cancer in contrast to only 65% of correctly classi®ed Gleason grade 4/5 samples. In the smaller group of isoechoic cancer samples, 97% were correctly classi®ed as cancer by ANNA whereas 71% of the hypoechoic cancer samples were correctly classi®ed as malignant. 25 It was concluded that the Arti®cial Neural Network Analysis of TRUS images signi®cantly reduced the number of false positives (1%) and false negatives (21%) and despite the fact that not all cancer samples were detected, cancerous regions were detected by ANNA in all of the patients who therefore would not have been misdiagnosed. 25 Finally, the session was concluded by Prof MK Brawer, Department of Urology, University of Washington, Seattle Washington, who discussed`Enhancing Performance of PSA Testing.' The majority of men with clinically localized prostate cancer that are treated by radical prostatectomy have clinically signi®cant cancer as judged from the volume, grade, cancer doubling time, and life expectancy of the patient 26 Recent studies show that it is possible to identify men with clinically signi®cant but curable cancer, though the lack of speci®city of the PSA measurements results in signi®cant numbers of men who need to be biopsied without having cancer. The high false positive rate is costly, generates patient anxiety, and puts stress on the diagnostic performance of the PSA-testing in terms of sensitivity, speci®city, positive and negative predictive value. Receiver Operation Characteristics (ROC) curve analysis can be used to ®nd optimal balance between cancer detection and a minimum of false positive results as given by the closest point of the curve to the upper left corner of the ROC curve. 27 Since the original reports in 1992 by Benson et al. 6 on PSA density, other investigators have also evaluated the utility of this concept, several of which concluded that it did not give any enhancement in cancer detection, though other studies show that PSA density perform signi®cantly better than PSA measurements alone in differentiating patients with cancer from those without cancer in the 4± 10 ng/mL range. 28, 29 The opposing ®ndings may be due to a signi®cant margin of error in measuring the prostate volume by TRUS, inter-individual variation of epithelial/ stromal ratio, 30 and variation in the biopsy sampling as it is more likely to detect the cancer in a smaller compared to a larger prostate. 31, 32 The PSA-velocity introduced by Carter et al 7 showed that an increase of 0.75 ng/mL per year or greater enhanced the detection of prostate cancer based on three PSA-measurements performed during a 7-year interval. Subsequently, the utility of short-term serial PSA measurements was analyzed by Porter et al 33 at University of Washington. Their data showed that there was no change in PSA-velocity which was useful to discriminate men with cancer from those without cancer using PSA-measurements taken at 1-and 2-year intervals. 33 This may be consistent with data showing that PSA-velocity is useful only if three consecutive measurements are used taken over a 2-year interval or greater. 34 This may be due to the random (up to 30) biological dayto-day variation of PSA-levels in serum, which is signi®-cantly higher in patients with benign histology than in those with cancer. 35 It is likely that the age-speci®c reference ranges (ASSRs) introduced by Oesterling et al 9 may be more adequate than a standard reference range for serum PSA to account for age-dependent increase in production and secretion of PSA. 36 Advantages of ASSRs are that they increase the sensitivity in men younger than 60 and increase the speci®city in men older than 60 y of age. 37 However, the dif®culty is to determine how much sensitivity can be sacri®ced for speci®city in the older men and The data reported by Lilja et al, 13 Stenman et al, 14 and Christensson et al 15 were the ®rst which identi®ed the different molecular forms of PSA in serum and showed that analysis of the free-to-total PSA ratio had the potential to enhance the performance of the measurements of total PSA alone. Recent research has focused on the clinical utility of these new methods and its range of ef®cacy. Catalona et al 38 determined that correlation of the free-to-total PSA ratio with the size of the gland provides additional information as patients with cancer in a gland smaller than 40 mL had signifantly lower median free-tototal PSA ratio compared to men with cancer in an enlarged gland. For the patient in the 4.0±10.0 ng/mL total PSA range with nonsuspicious DRE, the free-to-total PSA ratio may help to determine when to conduct a biopsy though further studies are required to delineate the most appropriate free-to-total PSA cutoff in large population based studies. This added information will help to reduce the number of unnecessary biopsies for patients in this dif®cult diagnostic range. Estimated from the data reported until now, it is likely that the free-tototal PSA ratio will ensure a sensitivity close to 90% while enhancing the speci®city such that nearly 30% of the unnecessary biopsies may be prevented. 39 
